Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You are negative every day so what’s the point??
I keep in regular contact
Thing move way faster than that when data lock announced. Running the data through the sap takes day or two.
Careful I can drink a lot of beer!
98% German ancestry!!! Ya!
Double or nothing for rest of year???
I live on beer!
I’m posting a 911 trade
You bing up the great point that this trial has created so many long term survivors!!!
Will we get the 911 trade again???
Lol
I try to stay in shape! Everything in moderation!
I will take that bet!
(As I hang up the phone....)
Lol
Life is good
Especially with beer
In moderation of course
Anything?? Ok I’ll take that bet!
I’m thinking of an offering after top line
From Novocures earnings release:
There were 2,751 active patients at September 30, 2019, representing 22% growth versus September 30, 2018, and one percent growth versus June 30, 2019. The increase in active patients was driven primarily by the ongoing benefit from continued growth in Optune prescriptions for patients with newly diagnosed GBM and by prescription growth in EMEA and Japan.
In the United States, there were 1,860 active patients at September 30, 2019, representing 16% growth versus September 30, 2018.
In Germany and other EMEA markets, there were 731 active patients at September 30, 2019, representing 26% growth versus September 30, 2018.
In Japan, there were 160 active patients at September 30, 2019, representing 132% growth versus September 30, 2018.
Additionally, 1,319 prescriptions were received in the three months ended September 30, 2019, representing six percent growth compared to the same period in 2018, and a three percent decrease compared to the three months ended June 30, 2019. The number of prescriptions for patients with newly diagnosed GBM continued to grow. In the three months ended September 30, 2019, 1,076 prescriptions were received for patients with newly diagnosed GBM, 82% of the total.
All hail the king pic.twitter.com/OoboE47V4Y
— Brad Loncar (@bradloncar) October 31, 2019
The 911 trade!! Halloween!!!!!
How many are still alive after all these years??
And when that process is over things will happen rapidly!
Heat post Mav!
Patience is nothing more than a refined sense of confidence.
And people running a scam to destroy a company trying to cure a deadly disease.
How many patients still alive after all these years???
https://www.scribd.com/document/411229128/A-Dendritic-Cell-Cancer-Vaccine-Shines-Brighter-for-Glioblastoma-Patients
Agree completely!
When they are ready things will move fast
You can thank woodford for the 12.40 price
Strong data!!
Standard of care!
And the new buyers are restricted from selling for 30 days.
Interesting. Could be timely.
This is actually standard for short term bridge loans. High interest rate because it’s a short term.
https://en.wikipedia.org/wiki/Bridge_loan
She is the one that kept the company afloat. She has worked tirelessly for over a decade.
Deserves every penny she makes on the share price increase of top line news. The big question is: will she desire to sell or keep ploughing on???
Enough with the empty platitudes
Crooks take money out of companies.
Northwest’s management invests their own money into the company!!
Ya he had some ego
The rise and fall of Woodford:
https://www.ft.com/content/2f077ae2-f19e-11e9-bfa4-b25f11f42901
In my opinion the 30 day share sale restriction implies that we will get news during this time.
Only thing that makes sense.
That’s some amazing research there
Nice sized bid
Ya a deal with big pharma
Just your personal opinion
Ummm. We know a Finished SAP is on the way. Just a matter of when.
Must be a bear dealing with 4 regulators
Ya and 100k wanting to buy at .2250
Bargain hunting!
Did anybody think that maybe the company is keeping their shareholder data base up to date????
2017!!!
From the February 6th Pr:
The PFS events have surpassed the 248-event threshold, but the OS events have not yet reached the 233-event threshold. Based upon the pace of OS events during the last six to eight months, the Company’s current anticipation is that it will be several months until the Trial reaches 233 OS events.